BioMarin Pharma (BMRN)
56.07
-0.37 (0.66%)
Upcoming Events
Latest Headlines
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $122 at Morgan Stanley
October 21, 2026 8:20 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $87 at JPMorgan
October 20, 2026 8:41 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $88 at UBS
October 15, 2026 9:21 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Barclays
October 14, 2026 4:18 AM - StreetInsider
Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
October 12, 2026 5:05 AM - StreetInsider
BioMarin presents Voxzogo skeletal dysplasia data at ASBMR meeting
October 9, 2026 9:05 AM - StreetInsider
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
October 9, 2026 9:05 AM - PR NewsWire
Form 8-K BIOMARIN PHARMACEUTICAL For: Oct 06
October 6, 2026 4:23 PM - SEC Filing
BioMarin names Cara Bauer as chief people officer
October 5, 2026 4:06 PM - StreetInsider
BioMarin Appoints Cara Bauer as Chief People Officer
October 5, 2026 4:05 PM - PR NewsWire
BioMarin shares five-year Pompe disease drug data at muscle congress
October 2, 2026 11:00 AM - StreetInsider
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
October 2, 2026 11:00 AM - PR NewsWire
Form 4 BIOMARIN PHARMACEUTICAL For: Sep 30 Filed by: Friberg Gregory R
October 1, 2026 4:23 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 24
September 30, 2026 4:16 PM - SEC Filing
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $97 at BMO Capital
September 16, 2026 7:57 AM - StreetInsider
BioMarin drops VOXZOGO development for Noonan syndrome children
September 15, 2026 8:34 AM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 15
September 15, 2026 8:32 AM - SEC Filing
Form 4 BIOMARIN PHARMACEUTICAL For: Sep 10 Filed by: Plenge Robert M
September 14, 2026 6:55 PM - SEC Filing
Form 3 BIOMARIN PHARMACEUTICAL For: Sep 10 Filed by: Plenge Robert M
September 14, 2026 6:48 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Sep 10
September 14, 2026 9:26 AM - SEC Filing
BioMarin adds Bristol Myers Squibb research chief to its board
September 14, 2026 9:05 AM - StreetInsider
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
September 14, 2026 9:05 AM - PR NewsWire
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
September 10, 2026 6:50 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
September 1, 2026 7:30 AM - StreetInsider
Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
September 1, 2026 6:58 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $60 at H.C. Wainwright
August 31, 2026 11:02 AM - StreetInsider
Morgan Stanley on BioMarin Pharmaceutical Inc. (BMRN): 'we think the settlement recognizes the value of BioMarin’s pioneering CNP innovation'
August 31, 2026 11:01 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $105 at Jefferies
August 31, 2026 11:00 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $109 at Raymond James
August 31, 2026 9:32 AM - StreetInsider
Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
August 31, 2026 9:22 AM - StreetInsider
Piper Sandler on BioMarin Pharmaceutical Inc. (BMRN): 'We Remain Bullish After Hosting Management Meetings'
August 26, 2026 9:22 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
August 19, 2026 6:43 AM - StreetInsider
Canaccord Reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN)
August 19, 2026 6:34 AM - StreetInsider
BMO Capital Starts BioMarin Pharmaceutical Inc. (BMRN) at Outperform
August 18, 2026 4:13 PM - StreetInsider
Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 17
August 18, 2026 8:39 AM - SEC Filing
BioMarin to acquire Alesta Therapeutics for $275M upfront
August 18, 2026 8:31 AM - StreetInsider
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
August 18, 2026 8:30 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $88 at Piper Sandler
August 17, 2026 7:43 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $111 at Barclays
August 17, 2026 4:51 AM - StreetInsider
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
August 10, 2026 9:05 AM - PR NewsWire
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $114 at Canaccord
August 10, 2026 7:00 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $70 at Stifel
August 7, 2026 10:22 AM - StreetInsider
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $97 at Oppenheimer
August 7, 2026 6:17 AM - StreetInsider
Form S-8 BIOMARIN PHARMACEUTICAL
August 6, 2026 5:26 PM - SEC Filing
BioMarin Pharma (BMRN) Tops Q2 EPS by 25c
August 6, 2026 5:13 PM - StreetInsider
Form 10-Q BIOMARIN PHARMACEUTICAL For: Jun 30
August 6, 2026 4:20 PM - SEC Filing
Form 8-K BIOMARIN PHARMACEUTICAL For: Aug 06
August 6, 2026 4:07 PM - SEC Filing
BioMarin Reports Second Quarter 2026 Financial and Operating Results
August 6, 2026 4:03 PM - PR NewsWire
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
July 30, 2026 9:00 AM - PR NewsWire
H.C. Wainwright Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
July 29, 2026 6:49 AM - StreetInsider
BioMarin and n-Lorem partner to develop ASO treatment for ReNU syndrome
July 27, 2026 9:05 AM - StreetInsider
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
July 27, 2026 9:05 AM - PR NewsWire
Full Article List
